Top Feature - Pharmaceutical Executive


Top Feature

Pharm Exec's 13th Annual Industry Audit

September 1, 2014

After a dip into negative territory in 2012, 2013 delivered a resurgence in sales revenues, but the turnaround only spotlights a larger trend: the growing divide between the big Pharmas and the more nimble players.

French Connections

July 31, 2014

The Galien Foundation and the French government investment agency UBIFRANCE have partnered to establish UBISTART, a transatlantic payout for the best in start-up innovations. William Looney reports.

FDA Abroad

July 21, 2014

FDA officials willing to relocate to far-flung global cities should be congratulated for their herculean efforts to protect American patients. But funding cuts hamper the Agency's international presence.

Pharm Exec's 2014 Dealmakers Outlook

July 10, 2014

As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead for M&A, licensing, and partnership activity.

Capturing the Real Value from a Pharma Spinout

July 9, 2014

The pharma spin market is moving up a gear as companies see the imperative to tap into brand value. Allen Gove explains how understanding what the company is about is critical to bolstering the value of the product.

The Graying of Clinical Trials

June 4, 2014

Elderly patients are underrepresented in clinical trials, but there are few obstacles to including this patient group in trials that cannot be overcome, writes Sydney Rubin.

India: Still a Growing Market

May 15, 2014

India must still be included in the list of promising potential markets for global pharmaceutical manufacturers, write Jill E. Sackman and Michael Kuchenreuther.

Bringing New Rx Drugs to Market in 2014

February 21, 2014

With 2014 shaping up to be a pivotal year for the American pharma industry, Tom Norton wonders how much longer American dominance in R&D spending can continue.

The Best Price for the Most Revenue

February 18, 2014

A global life-cycle management strategy should be baked into a drug's initial price at launch, write Alice Swearingen and Patrick Homer.


Click here